Jun. 21 at 6:55 AM
$NVO Novo presents test results of new weight 🚀🚀🚀🚀🚀
The drug amycretin can cause weight loss of 24 percent over 36 weeks, Novo Nordisk says at a meeting in Chicago
Novo Nordisk presented the full results of the first test phases of the weight loss drug amycretin on Friday in Chicago, USA.
At an annual meeting of the American Diabetes Association, Novo Nordisk reported that amycretin has helped patients lose more than 24 percent.
According to Novo Nordisk, the first test phases show that overweight and severely obese patients without diabetes lost 22 percent in 36 weeks with a weekly injection dose of 20 milligrams.
With an increased injection dose of 60 milligrams, the weight loss is 24.3 percent after 36 weeks.
Amycretin has also been tested in pill form, where patients have been given an increasing dose from 3 to 100 milligrams over a period of 12 weeks.
The patients who had reached 50 milligrams at the end of the trial period had an average weight loss of 10.4 percent.
